Changing of hepatitis C virus genotype patterns in France at the beginning of the third millenium:: The GEMHEP GenoCII Study

被引:130
作者
Payan, C
Roudot-Thoraval, F
Marcellin, P
Bled, N
Duverlie, G
Fouchard-Hubert, I
Trimoulet, P
Couzigou, P
Cointe, D
Chaput, C
Henquell, C
Abergel, A
Pawlotsky, JM
Hezode, C
Coudé, M
Blanchi, A
Alain, S
Loustaud-Ratti, V
Chevallier, P
Trepo, C
Gerolami, V
Portal, I
Halfon, P
Bourlière, M
Bogard, M
Plouvier, E
Laffont, C
Agius, G
Silvain, C
Brodard, V
Thiefin, G
Buffet-Janvresse, C
Riachi, G
Grattard, F
Bourlet, T
Stoll-Keller, F
Doffoel, M
Izopet, J
Barange, K
Martinot-Peignoux, M
Branger, M
Rosenberg, A
Sogni, P
Chaix, ML
Pol, S
Thibault, V
Opolon, P
Charrois, A
Serfaty, L
Fouqueray, B
机构
[1] CHU Angers, Angers, France
[2] CHU Henri Mondor, Serv Sante Publ, F-94010 Creteil, France
[3] Hop Beaujon, INSERM, Unite Rech, U481, Clichy, France
[4] CHU Hop Sud, Virol Lab, Amiens, France
[5] CHU Angers, Serv Med A, Angers, France
[6] Hop Pellegrin, Virol Lab, F-33076 Bordeaux, France
[7] Hop Pellegrin, Serv Hepatogastroenterol, F-33076 Bordeaux, France
[8] Hop Antoine Beclere, Serv Hepatogastroenterol, F-92141 Clamart, France
[9] CHU, Serv Hepatogastroenterol, Clermont Ferrand, France
[10] Hop Henri Mondor, Virol Lab, F-94010 Creteil, France
[11] Hop Henri Mondor, Serv Hepatogastroenterol, F-94010 Creteil, France
[12] Mol Biol Lab, Le Mans, France
[13] Serv Hepatogastroenterol, Le Mans, France
[14] CHU Dupuytren, Virol Lab, Limoges, France
[15] CHU Dupuytren, Serv Med Interne, Limoges, France
[16] Hop Hotel Dieu, Serv Hepatol & Gastroenterol, Lyon, France
[17] Hop Conception, Mol Biol Lab, Marseille, France
[18] Hop Conception, Serv Hepatol, Marseille, France
[19] Hop St Joseph, Dept Gastroenterol, Marseille, France
[20] CH, Unite Biol Mol, Meaux, France
[21] CHU, Meaux, France
[22] CHU, Virol Lab, Nice, France
[23] CHU Jean Bernard, Lab Microbiol B, Poitiers, France
[24] CHU Jean Bernard, Serv Hepatogastroenterol, Poitiers, France
[25] Hop Robert Debre, Virol Lab, Reims, France
[26] Hop Robert Debre, Serv Hepatogastroenterol, Reims, France
[27] Hop Charles Nicolle, Virol Lab, Rouen, France
[28] Hop Charles Nicolle, Polyclin Malad Digest, Rouen, France
[29] Hop Nord St Etienne, Virol Lab, St Etienne, France
[30] Inst Virol, Strasbourg, France
[31] Serv Hepatogastroenterol, Strasbourg, France
[32] Hop Purpan, Virol Lab, Toulouse, France
[33] Hop Purpan, Serv Hepatogastroenterol, Toulouse, France
[34] GH Cochin St Vincent Paul, Serv Virol, Paris, France
[35] GH Cochin St Vincent Paul, Serv Hepatol, Paris, France
[36] Hop Necker Enfants Malad, Virol Lab, Paris, France
[37] Hop Necker Enfants Malad, Serv Hepatol, Paris, France
[38] GH Pitie Salpetriere, Virol Lab, CERVI, Paris, France
[39] GH Pitie Salpetriere, Serv Hepatogastroenterol, Paris, France
[40] Lab Virol, Paris, France
[41] Serv Hepatol, Paris, France
[42] Hop Tenon, Serv Explorat Fonctionnelles, F-75970 Paris, France
[43] Hop Tenon, Serv Hepatogastroenterol, F-75970 Paris, France
[44] Hop St Antoine, INTS, F-75571 Paris, France
关键词
epidemiology; evolution; HCV genotypes; pathogenicity; treatment;
D O I
10.1111/j.1365-2893.2005.00605.x
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
This cross-sectional study aimed to investigate, during a short period between 2000 and 2001, in a large population of patients with chronic hepatitis C, the epidemiological characteristics of hepatitis C virus (HCV) genotypes in France. Data from 26 referral centres, corresponding to 1769 patients with chronic hepatitis C were collected consecutively during a 6-month period. HCV genotyping in the 5'-non-coding region (NCR) was performed in each center using the line probe assay (LiPA, in 63% of cases), sequencing (25%) or primer-specific polymerase chain reaction (PCR) (12%). HCV genotypes 1a, 1b, 2, 3, 4, 5, non-subtyped 1 and mixed infection were found in 18, 27, 9, 21, 9, 3, 11 and 1% of our population, respectively. HCV genotype distribution was associated with gender, age, source and duration of infection, alanine aminotransferase (ALT) levels, cirrhosis, alcohol consumption, hepatitis B virus (HBV) and human immunodeficiency virus (HIV) coinfection. In multivariate analysis, only the source of infection was the independent factor significantly associated with genotype (P = 0.0001). In conclusion, this study shows a changing pattern of HCV genotypes in France, with i.v. drug abuse as the major risk factor, an increase of genotype 4, and to a lesser extent 1a and 5, and a decrease of genotypes 1b and 2. The modification of the HCV genotype pattern in France in the next 10 years may require new therapeutic strategies, and further survey studies.
引用
收藏
页码:405 / 413
页数:9
相关论文
共 28 条
[11]   A natural intergenotypic recombinant of hepatitis C virus identified in St. Petersburg [J].
Kalinina, O ;
Norder, H ;
Mukomolov, S ;
Magnius, LO .
JOURNAL OF VIROLOGY, 2002, 76 (08) :4034-4043
[12]   Expertise of french laboratories in detection, genotyping, and quantification of hepatitis C virus RNA in serum [J].
Lefrère, JJ ;
Roudot-Thoraval, F ;
Lunel, F ;
Alain, S ;
Chaix, ML ;
Dussaix, E ;
Gassin, M ;
Izopet, J ;
Pawlotsky, JM ;
Payan, C ;
Stoll-Keller, F ;
Thibault, V ;
Trabaud, MA ;
Bogard, M ;
Branger, M ;
Buffet-Janvresse, C ;
Charrois, A ;
Defer, C ;
Laffont, C ;
Lerable, J ;
Levayer, T ;
Martinot-Peignoux, M ;
Mercier, B ;
Rosenberg, AR .
JOURNAL OF CLINICAL MICROBIOLOGY, 2004, 42 (05) :2027-2030
[13]   HCV genotypes in patients with liver disease of different stages and severity [J].
Mangia, A ;
Cascavilla, I ;
Lezzi, G ;
Spirito, F ;
Maertens, G ;
Parlatore, L ;
Saracco, G ;
Rizzetto, M ;
Andriulli, A .
JOURNAL OF HEPATOLOGY, 1997, 26 (06) :1173-1178
[14]   Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial [J].
Manns, MP ;
McHutchison, JG ;
Gordon, SC ;
Rustgi, VK ;
Shiffman, M ;
Reindollar, R ;
Goodman, ZD ;
Koury, K ;
Ling, MH ;
Albrecht, JK .
LANCET, 2001, 358 (9286) :958-965
[15]   Hepatitis C virus genotypes in France: relationship with epidemiology, pathogenicity and response to interferon therapy [J].
Martinot-Peignoux, M ;
Roudot-Thoraval, F ;
Mendel, I ;
Coste, J ;
Izopet, J ;
Duverlie, G ;
Payan, C ;
Pawlotsky, JM ;
Defer, C ;
Bogard, M ;
Gerolami, V ;
Halfon, P ;
Buisson, Y ;
Fouqueray, B ;
Loiseau, P ;
Lamoril, J ;
Lefrere, JJ ;
Marcellin, P .
JOURNAL OF VIRAL HEPATITIS, 1999, 6 (06) :435-443
[16]  
MARTINOTPEIGNOUX M, 1995, HEPATOLOGY, V22, P1050, DOI 10.1002/hep.1840220406
[17]   Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C [J].
McHutchison, JG ;
Gordon, SC ;
Schiff, ER ;
Shiffman, ML ;
Lee, WM ;
Rustgi, VK ;
Goodman, ZD ;
Ling, MH ;
Cort, S ;
Albrecht, JK .
NEW ENGLAND JOURNAL OF MEDICINE, 1998, 339 (21) :1485-1492
[18]  
Munoz G, 1998, REV MED CHILE, V126, P1035
[19]   Hepatitis C virus infection among pregnant women in Yaounde, Cameroon:: Prevalence, viremia, and genotypes [J].
Njouom, R ;
Pasquier, C ;
Ayouba, A ;
Sandres-Sauné, K ;
Mfoupouendoun, J ;
Lobe, MM ;
Tene, G ;
Thonnon, J ;
Izopet, J ;
Nerrienet, E .
JOURNAL OF MEDICAL VIROLOGY, 2003, 69 (03) :384-390
[20]  
Nousbaum JB, 1998, B SOC PATHOL EXOT, V91, P29